title: [Dopamine agonists--pharmacological similarities and differences].
abstract: Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized by selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. Considerable advances made in defining the aetiology, pathogenesis and pathology of PD have resulted in the development and rapid expansion of the treatment. Dopamine receptor agonists play increasingly important roles in antiparkinsonian therapy. Pharmacological and pharmacokinetic properties of these agents are briefly reviewed and followed by a detailed summary of available literature concerning controlled trials in Parkinson's disease.
authors.affiliation: Klinika Neurologii, Pomorska Akodemia Medyczna w Szczecinie. khanczar@rl.pam.szczecin.pl
authors.forename: Krystyna
authors.initials: K
authors.lastname: Honczarenko
authors.forename: Monika
authors.initials: M
authors.lastname: Białecka
mesh_terms: D000978:Antiparkinson Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D011954:Receptors, Dopamine